After Mortality-Marred Year, Sarepta Looks Ahead to Catalyst-Rich 2026

Why It Matters

The pivot to high‑value siRNA assets could restore investor confidence and unlock over $1 billion market opportunities, while resolving safety concerns that have plagued Sarepta’s gene‑therapy business.

Key Takeaways

• Jefferies sees +25‑50% move from siRNA pipeline.
• SRP‑1001/1003 Phase I/II data due Q1 2026.
• PMO sales $259M Q4, near $966M FY 2025.
• DMD exon‑skippers failed trial; FDA meeting pending.
• Huntington’s siRNA SRP‑1005 IND filed, Phase I 2026.

Pulse Analysis

Sarepta Therapeutics endured a tumultuous 2025, marked by patient deaths linked to its Elevidys gene‑therapy and a sharp decline in confidence for its Duchenne muscular dystrophy (DMD) exon‑skipping drugs. In response, the company executed a strategic pivot toward RNA‑interference therapeutics, leveraging Arrowhead Pharmaceuticals’ siRNA platform. This move aligns with a broader industry trend where biotech firms diversify pipelines to mitigate risk and tap into the growing $1‑plus‑billion market potential of rare‑disease siRNA treatments.

The new pipeline centers on three Arrowhead‑partnered candidates. SRP‑1001 targets facioscapulohumeral muscular dystrophy and SRP‑1003 addresses myotonic dystrophy type 1, both slated to deliver Phase I/II readouts in the first quarter of 2026. A third asset, SRP‑1005 for Huntington’s disease, has already received a clinical‑trial application and aims to begin Phase I enrollment in early 2026. Analysts at Jefferies argue that successful data could catalyze a 25‑50% rally in Sarepta’s stock, reflecting the high unmet need and premium pricing typical of rare‑disease siRNA drugs.

Commercially, Sarepta’s phosphorodiamidate morpholino oligomer (PMO) portfolio posted $259.2 million in Q4 revenue, nearly $966 million for the full year, modestly outpacing consensus expectations despite flat year‑on‑year growth. However, the failure of Vyondys 53 and Amondys 45 in a confirmatory DMD trial and the pending FDA meeting introduce regulatory uncertainty. If the company secures a clear path to full approval, analysts estimate an additional 25% upside. Overall, the blend of a revitalized siRNA pipeline and steady PMO cash flow positions Sarepta to rebound, but execution risk remains high as it navigates safety scrutiny and regulatory hurdles.